Genetic variations in SREBP-1 and LXRa are not directly associated to PCOS but contribute to the physiological specifics of the syndrome

Molecular Biology Reports

Volumn 39, Issue 6, 2012, Pages 6835-6842

  Knebel, Birgit ^a   Janssen, Onno E ^b   Hahn, Susanne ^c   Jacob, Sylvia ^a   Nitzgen, Ulrike ^a   Haas, Jutta ^d   Muller Wieland, Dirk ^d   Kotzka, Jorg ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b ENDOKRINOLOGIKUM HAMBURG   (Germany)

^c Medical Practice for Endocrinology   (Germany)

^d Budapest An der Schön Klinik Hamburg Eilbek Dehnhaide   (Germany)

Author keywords

Insulin sensitivity; Lipid metabolism; Obesity; PCOS; Susceptibility genes

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIVER X RECEPTOR ALPHA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LXR ALPHA GENE; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; NUCLEOTIDE SEQUENCE; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PHENOTYPE; SREBF 1 GENE; SREBP 1 GENE; SREBP 1A GENE; SREBP 1C GENE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; HUMANS; INSULIN; LINKAGE DISEQUILIBRIUM; ORPHAN NUCLEAR RECEPTORS; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; YOUNG ADULT;

EID: 84864280045     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-1508-0     Document Type: Article

References (38)

1. Goodarzi MO, Dumesic DA, Chazenbalk G et al (2011) Poly-cystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 7:219-231
2. Wild RA, Carmina E, Diamanti-Kandarakis E et al (2010) Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) society. J Clin Endocrinol Metab 95:2038-2049
3. Toulis KA, Goulis DG, Mintziori G et al (2011) Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update. doi:10.1093/humupd/dmr025
4. Zawadski JK, Dunai FA (1992) Diagnostic criteria for polycystic ovary syndrome: toward a rational approach. In: Dunaif A, Gi-vens JR, Hasettine FP (eds) Polycystic ovary syndrome. Blackwell Scientific Publications, Boston, pp 377-384
5. Rotterdam ESHRE/ASRMSponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41-47
6. Azziz R, Carmina E, Dewailly D, Androgen Excess Society et al (2006) Androgen excess society position statement: criteria for defining polycystic ovary syndrome as a predominantly hyper-androgenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 91:4237-4245 (Pubitemid 44833391)
7. Salesi M, Bravo-Vera R, Sheikh A et al (2004) Pathogenesis of the polycystic ovary syndrome: what is the role of obesity? Metabolism 53:358-376 (Pubitemid 38684698)
8. Venkatesan AM, Dunaif A, Corbould A (2001) Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Prog Horm Res 56:295-308
9. Azziz R (2004) PCOS: a diagnostic challenge. Reprod Biomed Online 8:644-648 (Pubitemid 38744941)
10. O'Meara NM, Blackman JD, Ehrmann DA et al (1993) Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 76:1241-1247 (Pubitemid 23155443)
11. Hudecova M, Holte J, Olovsson M et al (2009) Long-term follow-up of patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve. Hum Reprod 24:1176-1183
12. Sam S, Dunaif A (2003) Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 14:365-370 (Pubitemid 37236957)
13. Rebuffé-Scrive M, Cullberg G, Lundberg PA et al (1989) Anthropometric variables and metabolism in polycystic ovarian disease. Horm Metab Res 21:391-397 (Pubitemid 19182759)
14. Meyer C, McGrath BP, Teede HJ (2005) Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 90:5711-5716 (Pubitemid 41415480)
15. Lo JC, Feigenbaum SL, Yang J et al (2006) Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 91:1357-1363
16. Wild RA, Rizzo M, Clifton S et al (2011) Lipid levels in poly-cystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 95:1073-1079
17. Mukherjee S, Maitra A (2010) Molecular & genetic factors contributing to insulin resistance in polycystic ovary syndrome. Indian J Med Res 131:743-760
18. Azziz R, Dumesic DA, Goodarzi MO (2010) Polycystic ovary syndrome: an ancient disorder? Fertil Steril 95:1544-1548
19. Deligeoroglou E, Kouskouti C, Christopoulos P (2009) The role of genes in the polycystic ovary syndrome: predisposition and mechanisms. Gynecol Endocrinol 25:603-609
20. Chen ZJ, Zhao H, He L et al (2011) Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet 43:55-59
21. Goodarzi MO, Louwers YV, Taylor KD et al (2011) Replication of association of a novel insulin receptor gene polymorphism with polycystic ovary syndrome. Fertil Steril 95:1736-1741
22. Zhao C, Dahlman-Wright K (2010) Liver X receptor in cholesterol metabolism. J Endocrinol 204:233-240
23. Raghow R, Yellaturu C, Deng X et al (2008) SREBPs: the crossroads of physiological and pathological lipid homeostasis. Trends Endocrinol Metab 19:65-73 (Pubitemid 351317897)
24. Ferré P, Foufelle F (2007) SREBP-1c transcription factor and lipid homeostasis: clinical perspective. Horm Res 68:72-82 (Pubitemid 47026704)
25. Harada N, Yonemoto H, Yoshida M et al (2008) Alternative splicing produces a constitutively active form of human SREBP-1 Biochem. Biophys Res Commun 368:820-826
26. Hahn S, Fingerhut A, Khomtsiv U et al (2005) The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 62:573-579 (Pubitemid 40646724)
27. Knebel B, Janssen OE, Hahn S et al (2008) Increased low grade inflammatory serum markers in patients with polycystic ovary syndrome (PCOS) and their relationship to PPARgamma gene variants. Exp Clin Endocrinol Diabetes 116:481-486
28. Knebel B, Janssen OE, Hahn S et al (2009) Combined analyses of paraoxonase-1 and IGF-2 polymorphism in polycystic ovary syndrome. Dtsch Med Wochenschr 134:1040-1046
29. Vernia S, Eberle D, Hernandez Mijares A et al (2006) A rare missense mutation in a type 2 diabetes subject decreases the transcriptional activity of human sterol regulatory element binding protein-1. Hum Mutat 27:212
30. Choukem SP, Boudou P, Sobngwi E et al (2009) The polymorphism Arg585Gln in the gene of the sterol regulatory element binding protein-1 (SREBP-1) is not a determinant of ketosis prone type 2 diabetes (KPD) in Africans. Diabetes Metab 35:20-24
31. Kotzka J, Knebel B, Janssen OE et al (2011) Identification of a gene variant in the master regulator of lipid metabolism SREBP-1 in a family with a novel form of severe combined hypolipidemia. Atherosclerosis 218:134-143
32. Ketterer C, Müssig K, Machicao F et al (2011) Genetic variation within the NR1H2 gene encoding liver X receptor b associates with insulin secretion in subjects at increased risk for type 2 diabetes. J Mol Med 89:75-81
33. Price ET, Pacanowski MA, Martin MA et al (2011) Liver X receptor a gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study. Pharmacogenet Genomics 21:333-340
34. Dahlman I, Nilsson M, Jiao H et al (2006) Liver X receptor gene polymorphisms and adipose tissue expression levels in obesity. Pharmacogenet Genomics 16:881-889 (Pubitemid 44772806)
35. Legry V, Cottel D, Ferrières J et al (2008) Association between liver X receptor alpha gene polymorphisms and risk of metabolic syndrome in French populations. Int J Obes (Lond) 32:421-428 (Pubitemid 351414804)
36. Legry V, Bokor S, Beghin L, HELENA Study Group et al (2011) Associations between common genetic polymorphisms in the liver X receptor alpha and its target genes with the serum HDL-cholesterol concentration in adolescents of the HELENA Study. Atherosclerosis 216:166-169
37. Ewens KG, Jones MR, Ankener W et al (2011) Type 2 diabetes susceptibility single-nucleotide polymorphisms are not associated with polycystic ovary syndrome. Fertil Steril 95:2538-2541
38. Ewens KG, Jones MR, Ankener W et al (2011) FTO and MC4R gene variants are associated with obesity in polycystic ovary syndrome. PLoS One 6:e16390